A Phase Ib Randomized Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK7009 in Hepatitis C Infected Patients.

Trial Profile

A Phase Ib Randomized Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK7009 in Hepatitis C Infected Patients.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Aug 2015

At a glance

  • Drugs Vaniprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 05 May 2010 Actual patient number added as 40, Primary endpoint changed from clinical response to viral load as reported by ClinicalTrials.gov.
    • 20 May 2009 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
    • 20 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top